Pediatrics Doctors in Taos, NM Accepting Medicare

4 Pediatrics doctors found. Showing 1 - 4

Dr. Richard Michael Rembecki, MD, PHD Pediatrics Medicare: Medicare Enrolled Practice Location: 1397 Weimer Rd, Taos, NM 87571 Phone: 800-755-6236

Dr. Charles W Anderson, MEDICAL DOCTOR Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 123 Cruz Alta, Taos, NM 87571 Phone: 505-758-8651    Fax: 505-758-7811

Sylvia Fernandez Villarreal, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1393 Weimer Rd, Taos, NM 87571 Phone: 505-758-8651

John Alan Macfarlane, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 630 Paseo Del Pueblo Sur Ste 150, Box 5436 Ndcbu, Taos, NM 87571 Phone: 575-758-3005

News Archive

Depomed submits Serada NDA with FDA for treatment of menopausal hot flashes

Depomed, Inc. today announced that it has submitted a New Drug Application (NDA) for Serada to the United States Food and Drug Administration. Serada is Depomed's proprietary extended release formulation of gabapentin in development for the treatment of menopausal hot flashes.

Bad news for women with sleep apnea: The body's autonomic responses more diminished in women

There's more bad news for women with sleep apnea. A new study from the UCLA School of Nursing shows that the body's autonomic responses - the controls that impact such functions as blood pressure, heart rate and sweating - are weaker in people with obstructive sleep apnea but are even more diminished in women.

Cardiovascular and Renal Drugs Advisory Committee recommends FDA approval of J&JPRD's rivaroxaban

Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (J&JPRD) announced today that the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee recommended approval of rivaroxaban, a novel, once-daily, oral anticoagulant, for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.

NovaBay third quarter net loss increases to $1.6 million

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, has reported third quarter financial results and highlighted the clinical progress of its in-house programs.

Read more Medical News

› Verified 2 days ago